Related Experiment Video
Updated: May 24, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Multiple biomarkers for risk prediction in chronic heart failure
Bonnie Ky1, Benjamin French, Wayne C Levy
1Penn Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. bonnie.ky@uphs.upenn.edu
Circulation. Heart Failure
|February 25, 2012
Summary
A new multimarker score significantly improves risk prediction for chronic heart failure patients. This score, using diverse biomarkers, enhances prognostic accuracy beyond existing clinical models for adverse events.
Area of Science:
- Cardiology
- Biomarker Research
- Prognostic Modeling
Background:
- Chronic heart failure prognosis often relies on clinical evaluation.
- Prior studies suggested biomarker panels for heart failure prognostication.
- The added value of biomarker panels over clinical assessment remained unclear.
Purpose of the Study:
- To evaluate if a contemporary multimarker score improves risk prediction in chronic systolic heart failure.
- To compare the performance of a multimarker score against the established Seattle Heart Failure Model (SHFM).
Main Methods:
- A multicenter cohort of 1513 chronic systolic heart failure patients was analyzed.
- A biomarker panel including hs-CRP, MPO, BNP, sFlt-1, troponin I, sTLR-2, creatinine, and uric acid was measured.
- A multimarker score was calculated and compared with the SHFM for predicting adverse outcomes (death, transplant, VAD).
Main Results:
- Patients in the highest tertile of the multimarker score had a 13.7-fold increased risk of adverse outcomes.
- The multimarker score independently improved risk prediction beyond the SHFM (aHR 6.80).
- Adding the score to the SHFM significantly improved AUC (0.803 vs 0.756) and reclassified patients (NRI 25.2%).
Conclusions:
- A multimarker score derived from diverse biological pathways significantly enhances risk prediction in ambulatory chronic heart failure.
- This biomarker-based score offers superior prognostic capability compared to current clinical metrics.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...